Novartis burnishes prospects for its big asthma drug with positive PhIII data from a similar treatment
Novartis has some good news to share on the asthma front as it sets the scene for a blockbuster Phase III readout.
The star today is low dose QMF149, a combo of the long-acting beta agonist (LABA) indacaterol acetate and the corticosteroid mometasone furoate. The once-daily inhalation beat a corticosteroid monotherapy on all primary and secondary endpoints, including forced expiratory volume and asthma control as measured by a questionnaire.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.